(Total Views: 521)
Posted On: 09/06/2019 6:12:44 PM
Post# of 145912
I agree two would be killer, Lalezari could have been thinking about this combo option when he said it. Even ViiV tried Dolutegravir as mono first, because a first ever mono would be a notch above killer imo, less side effects, cost to compete with 2 or 3 drug combo vs 1 drug, almost unstoppable. I believe he was thinking about overall efficacy with 2 drugs vs 1 drug, which is why I thought the receptor occupancy test to identify the responders with high accuracy was the key. We will see if the overlap alone does it.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)